\
&
Contact us
\
&
Contact us
Published on | 4 years ago
Programmes COSTThe next collection date for the COST Open Call OC-2021-1 is set on 29 October 2021 at 12:00 noon (CET).
In the context of this Open Call, please find below an overview of some COST Info Sessions in the near future that might be of your interest:
This open online info day is organized by COST and will be livestreamed via COST's YouTube channel and zoom.
Fore more information on this event and agenda click here.
This joint webinar is organized by the Estonian Liaison Office for EU RTD (ELO) and Lithuanian RDI Liaison Office LINO in collaboration with COST and will present the opportunities provided by COST with specific focus on the evaluation procedures and opportunities to contribute as evaluators.
For more information on the agenda and registration click here.
The Belgian COST Contact Points will organize a COST Info Session for Proposers in order to support researchers/actors that are preparing a COST proposal as the Main Proposer for the next COST Open Call OC-2021-1.
More information will be available soon.
You can also check the NCP Flanders events page for more details on these COST events.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
